Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of LY3844583 in Healthy Participants and Patients With Atopic Dermatitis
jRCT2031220745Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of LY3844583 in atopic dermatitis (AD) (6 arms), sponsored by Eli Lilly and Company. Started Apr 2023; status: completed.
02
Drugs
LY3844583
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031220745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220745.